<DOC>
	<DOCNO>NCT02229942</DOCNO>
	<brief_summary>The hypothesis subgroup patient Chronic Fatigue Syndrome/ Myalgic Encephalopathy ( CFS/ME ) chronically activate immune system may benefit B-lymphocyte treatment use monoclonal anti-CD20 antibody rituximab induction maintenance treatment .</brief_summary>
	<brief_title>B-lymphocyte Depletion Using Rituximab Chronic Fatigue Syndrome/ Myalgic Encephalopathy ( CFS/ME ) . A Randomized Phase-III Study .</brief_title>
	<detailed_description>We publish case series pilot patient observation B-cell depletion Chronic Fatigue Syndrome/ Myalgic Encephalopathy ( CFS/ME ) ( Fluge Mella , BMC Neurol , 2009 ) . Subsequently , publish small randomized double-blind phase II study use rituximab induction two infusion two week apart ( Fluge et al , Plos One , 2011 ) . We complete open label phase II study 29 patient use rituximab induction maintenance treatment ( six rituximab infusion 15 month , follow-up three year , unpublished ) . We hypothesize subgroup patient Chronic Fatigue Syndrome/ Myalgic Encephalopathy ( CFS/ME ) chronically activate immune system involve B-lymphocytes , possibly variant autoimmune disease , patient may benefit B-cell depletion therapy . Three substudies perform : Endothelial function : assessment Flow-Mediated Dilation skin microcirculation baseline repeat time interval 17-21 month . Cardiopulmonary exercise test two follow day : assessment baseline repeat time interval 17-21 month . Gastrointestinal function : assessment baseline repeat time interval 17-21 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients Chronic Fatigue Syndrome/ Myalgic Encephalopathy ( CFS/ME ) accord Canadian diagnostic criterion ( Carruthers , 2003 ) Duration CFS/ME disease 215 year . For patient mild CFS/ME duration disease must 515 year . Mild , Mild/Moderate , Moderate , Moderate/Severe Severe CFS/ME may include Signed informed consent Patients fatigue , comply Canadian diagnostic criterion ( 2003 ) Duration CFS/ME &lt; 2 year &gt; 15 year Patients severe CFS/ME Pregnancy lactation . Previous malignant disease ( except basal cell carcinoma skin uterine cervical dysplasia ) Previous treatment Blymphocyte deplete therapeutic monoclonal antibody , rituximab Previous longterm systemic immunosuppressive treatment , include drug cyclosporine , azathioprine , mycophenolate mofetil , except steroid treatment e.g . obstructive lung disease autoimmune diseases ulcerative colitis Severe endogenous depression Lack ability adhere protocol Known multiallergy clinically assess risk rituximab infusion Reduced kidney function ( serum creatinine &gt; 1,5x upper normal level ) Reduced liver function ( serum bilirubin transaminase &gt; 1,5x upper normal level ) Known HIV positivity , previous hepatitis B hepatitis C Evidence ongoing , active clinically relevant infection Known immunodeficiency risk therapeutic Bcell depletion , hypogammaglobulinemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Fatigue Syndrome ( CFS )</keyword>
	<keyword>Myalgic Encephalitis ( ME )</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B-lymphocyte depletion</keyword>
	<keyword>B-cell depletion</keyword>
</DOC>